All In Biotech

Drug Trial Radar · NCT04141787

Ceftriaxone as Home IV for Staph Infections

Ceftriaxone as Home Intravenous Therapy for Deep-Seated Staphylococcal Infections, a Randomized Non-Inferiority Trial

Last checked: Nov 19, 2026Latest source record: Oct 28, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 310 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

310

Planned (sponsor's estimate)

Start

Jul 11, 2019

Primary completion

Jul 2023

Study completion Mar 30, 2024

Sponsor

Lead sponsor
Vancouver Island Health AuthorityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 28, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Patients who are admitted to hospital with serious infections, such as those in bone, joints or spine, require a long course of intravenous (IV) antibiotics. After an initial treatment course in hospital or through a dedicated outpatient antibiotic program many patients can complete their treatment course at home. Such infections are often caused by bacteria called Staphylococci, and currently there are three antibiotic options used routinely. A fourth antibiotic, ceftriaxone, is a promising alternative; it is also effective against Staphylococci, and is more convenient, less costly and easier to give at home, however, it has not been studied thoroughly in a prospective manner. This study will compare ceftriaxone to routinely used antibiotics (cloxacillin, cefazolin or daptomycin) to see if ceftriaxone is equally as safe and efficacious in curing deep-seated Staphylococcal infections in patients receiving home IV antibiotics. Patients with deep-seated infections caused by methicillin-susceptible Staphylococcus aureus (MSSA) or coagulase-negative Staphylococcal species will be randomly assigned home IV treatment with ceftriaxone OR one of the three other antibiotics before leaving the hospital. Patients will then receive usual care from an Infectious Disease physician and Home IV team. The study team will assess whether cure has been achieved by the end of the IV treatment, follow-up at 6 months to see if patients remain infection-free, and record any side-effects of treatment. The overall goal is to determine whether ceftriaxone can be considered non-inferior to usual antibiotic treatment in treating Staphylococcal infections in a home IV setting.

Conditions

  • Staphylococcal Infections
  • Osteomyelitis
  • CNS Infection
  • Septic Arthritis
  • Diabetic Foot Infection
  • Vertebral Osteomyelitis
  • Abscess
  • Coagulase Negative Staphylococcal Infection

Interventions

  • CeftriaxoneDrug

    Participants with methicillin-sensitive deep-seated staphylococcal infections eligible for treatment on home IV will be randomly assigned to a "treatment" group of ceftriaxone or "standard therapy/usual antibiotics" with either cloxacillin, cefazolin or daptomycin. The treatment with one of the three "standard therapies/usual antibiotics" will be left to the discretion of the treating Infectious Disease doctor, in line with current standards of practice.

  • Usual Antibiotics (Cloxacillin, Cefazolin, Daptomycin)Drug

    Participants with methicillin-sensitive deep-seated staphylococcal infections eligible for treatment on home IV will be randomly assigned to a "treatment" group of ceftriaxone or "standard therapy/usual antibiotics" with either cloxacillin, cefazolin or daptomycin. The treatment with one of the three "standard therapies/usual antibiotics" will be left to the discretion of the treating Infectious Disease doctor, in line with current standards of practice.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinical cure rate of deep-seated methicillin sensitive Staphylococcal infectionsTime frame: Up to 6 months post-randomization

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Royal Jubilee Hospital

    Victoria, British Columbia, Canada · Recruiting

  • Victoria General Hospital

    Victoria, British Columbia, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.